| scholarly article | Q13442814 |
| P50 | author | Jan-Georg Wojtyniak | Q60320130 |
| Angelika Vollmar | Q21253616 | ||
| P2093 | author name string | Martin Müller | |
| Melanie Ulrich | |||
| Georg J Arnold | |||
| Thomas Fröhlich | |||
| Doris Mayr | |||
| Stefan Zahler | |||
| Giorgio Scita | |||
| Alexander Gerbes | |||
| Simon Rothenfußer | |||
| Thorsten Lehr | |||
| Johanna Pachmayr | |||
| Maximilian A Ardelt | |||
| Dario Parazzoli | |||
| Lars König | |||
| Carina Atzberger | |||
| Veronika Kanitz | |||
| Emanuele Martini | |||
| Martina Meßner | |||
| Laura Posselt | |||
| Petra Cantonati | |||
| P2860 | cites work | Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells | Q38801405 |
| Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma | Q38812372 | ||
| The Emerging Role of Cdk5 in Cancer | Q39029140 | ||
| The V-ATPase-inhibitor archazolid abrogates tumor metastasis via inhibition of endocytic activation of the Rho-GTPase Rac1. | Q39276731 | ||
| Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells | Q39677393 | ||
| Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). | Q39991768 | ||
| Inhibition of the V-ATPase by Archazolid A - a new strategy to inhibit EMT. | Q40107375 | ||
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study | Q43691230 | ||
| Cdk5 Regulation of the GRAB-Mediated Rab8-Rab11 Cascade in Axon Outgrowth | Q46201086 | ||
| Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma | Q47370746 | ||
| Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. | Q47576283 | ||
| Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma | Q48140297 | ||
| Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial | Q50046367 | ||
| SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. | Q50454368 | ||
| Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer. | Q52940505 | ||
| Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. | Q53179931 | ||
| A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib. | Q53212995 | ||
| Efficacy and safety of dinaciclib vs ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia. | Q53544952 | ||
| Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma. | Q54196716 | ||
| Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach. | Q55068022 | ||
| Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma | Q73083466 | ||
| Global cancer statistics | Q22241238 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. | Q27853079 | ||
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma | Q33409641 | ||
| Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial | Q33410643 | ||
| Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. | Q33418705 | ||
| Involvement of DNA damage response pathways in hepatocellular carcinoma | Q33616812 | ||
| Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. | Q33907588 | ||
| A decade of CDK5. | Q34093501 | ||
| Cdk5 behind the wheel: a role in trafficking and transport? | Q34537614 | ||
| Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase IIα degradation in hepatocellular carcinoma cells | Q34681633 | ||
| Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial | Q34786090 | ||
| Hepatocellular carcinoma: clinical frontiers and perspectives | Q35112053 | ||
| c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma | Q35235798 | ||
| In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. | Q35250612 | ||
| Phase 1/2 study of everolimus in advanced hepatocellular carcinoma | Q36160273 | ||
| Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma | Q36622264 | ||
| Endocytosis and signaling: cell logistics shape the eukaryotic cell plan | Q37980726 | ||
| The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis | Q38169563 | ||
| Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature. | Q38181289 | ||
| Cdk5 regulates multiple cellular events in neural development, function and disease. | Q38213140 | ||
| Treatment of intermediate-stage hepatocellular carcinoma | Q38236876 | ||
| Epithelial-to-Mesenchymal Plasticity Harnesses Endocytic Circuitries | Q38376446 | ||
| Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma | Q38612996 | ||
| Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma | Q38635603 | ||
| Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 376-393 | |
| P577 | publication date | 2018-12-22 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy | |
| P478 | volume | 69 |
| Q92475195 | A kinase of many talents: non-neuronal functions of CDK5 in development and disease |
| Q93185953 | CDK5 neutralizes the tumor suppressing effect of BIN1 via mediating phosphorylation of c-MYC at Ser-62 site in NSCLC |
| Q64388096 | CRISPR/Cas9 for overcoming drug resistance in solid tumors |
| Q89998270 | From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma |
| Q89528234 | New landscapes and horizons in hepatocellular carcinoma therapy |
| Q90333546 | Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma |
Search more.